TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00668057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5 mg Vardenafil orally 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg Vardenafil orally 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 20 mg Vardenafil orally 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg matching placebo
Study: NCT04374526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma
Description: ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
Study: NCT01772017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Advancement Retainer Device
Description: Tongue Advancement Retainer Device
Study: NCT04250246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab plus guadecitabine
Description: Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab plus nivolumab
Description: Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years.
Study: NCT00668057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg matching placebo
Study: NCT02074384

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor
Description: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
Study: NCT02750436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided
Description: This group will be treated using an ultrasound imaging device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided
Description: This group will be treated using a fluoroscopy imaging device
Study: NCT02127931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Groundskeeper for ADHD group
Description: Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Groundskeeper for control group
Description: Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
Study: NCT03117686

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro
Study: NCT02723539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBN-101
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application
Study: NCT04084444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T8 tablet 0.5mg
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T8 tablet 1mg
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank control.
Study: NCT02074384

Intervention type: DEVICE
Group type: OTHER
Intervention: Self Monitoring Blood Glucose
Description: Participants will use their own SMBG device.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinician
Description: Survey of clinicians after study visits
Study: NCT01934166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg
Description: One single oral dose of 18 mg
Study: NCT03958149

Intervention type: DEVICE
Group type: OTHER
Intervention: spinal collar
Description: cervical collar to immobilise the cervical spine
Study: NCT03508206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SBRP
Description: SBRP capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo capsules
Study: NCT04085614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
Description: Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
Description: Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
Study: NCT02680314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
Study: NCT03937752

Intervention type: OTHER
Intervention: 3D endodanal ultrasound
Description: Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
Study: NCT05533788

Intervention type: DRUG
Group type: OTHER
Intervention: ABSK091 tablet
Description: ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors

Intervention type: DRUG
Group type: OTHER
Intervention: ABSK091 tablet
Description: ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
Study: NCT04759729

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic and vitamin D
Description: Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo and vitamin D
Description: Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
Study: NCT03303131

Intervention type: OTHER
Intervention: Discharge from community-based management
Description: Comparison of patient characteristics and treatment outcomes between two groups

Intervention type: OTHER
Intervention: Discharge from community-based management
Description: Comparison of patient characteristics and treatment outcomes between two groups
Study: NCT04627389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orbicularis oris muscle Z- plasty modification of modified millard technique
Description: After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
Study: NCT05011604

Intervention type: DEVICE
Group type: OTHER
Intervention: Full-Digital Workflow in Single-Tooth Implant Rehabilitation
Description: For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented.
Study: NCT00450801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV, Days 1 of all cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
Study: NCT02064335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
Study: NCT00450801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Granisetron 1 mg IV on Day 1, Cycle 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: Decadron 10 mg IV on Day 1, Cycles 1 and 3
Study: NCT03713229

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for anal squamous intraepithelial lesions
Description: digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for anal squamous intraepithelial lesions
Description: digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for anal squamous intraepithelial lesions
Description: digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
Study: NCT02767037

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sudoscan and clinical assessment
Description: The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sudoscan and clinical assessment
Description: The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sudoscan and clinical assessment
Description: The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sudoscan and clinical assessment
Description: The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Skin biopsy
Description: Evaluation of the denervation and synuclein deposition of skin biopsy

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Evaluation of the denervation and synuclein deposition of skin biopsy

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Evaluation of the denervation and synuclein deposition of skin biopsy

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Evaluation of the denervation and synuclein deposition of skin biopsy
Study: NCT00750685

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Smooth Becker 50 Expander/Breast Implant
Description: The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
Study: NCT04506333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D UA-651 Blood Pressure Monitor
Description: Test device to be validated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC 740-N Manual Sphygmomanometer
Description: Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC 740-N Manual Sphygmomanometer
Description: Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
Study: NCT04627389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified millard technique
Description: no z-plasty modification
Study: NCT00805194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus docetaxel
Description: placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 plus docetaxel
Description: BIBF 1120 2 times daily along with standard therapy of docetaxel
Study: NCT00958230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dCell Vascular Patch
Description: Implantation of a dCell Vascular Patch as part of an Endarterectomy
Study: NCT04506333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC 740-N Manual Sphygmomanometer
Description: Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
Study: NCT01660503

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 grams SCF
Description: Given in snack foods (muffins and flavored beverage)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 grams SCF
Description: Given in snack foods (muffins and flavored beverage)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 grams SCF
Description: Given in snack foods (muffins and flavored beverage)
Study: NCT00598325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)
Description: 1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)
Description: 1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
Study: NCT00771056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg by mouth daily x 1 year
Study: NCT01242852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))
Description: Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS \& hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions \& endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
Study: NCT05508893

Intervention type: RADIATION
Group type: OTHER
Intervention: CT Angiography
Description: A CTA will be performed on asymptomatic individuals

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise stress test
Description: A routine exercise stress test will be performed on a bicycle
Study: NCT02708420

Intervention type: DEVICE
Group type: OTHER
Intervention: Glidescope
Description: This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.

Intervention type: DEVICE
Group type: OTHER
Intervention: Macintosh Laryngoscope
Description: This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
Study: NCT02474251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure device
Description: GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure device
Description: GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
Study: NCT00734721

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative information and perioperative care
Description: Patients receive different information and care in addition to the basic medical consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative information and perioperative care
Description: Patients receive different information and care in addition to the basic medical consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative information and perioperative care
Description: Patients receive different information and care in addition to the basic medical consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative information and perioperative care
Description: Patients receive different information and care in addition to the basic medical consultation.
Study: NCT03539991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete online courses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meeting
Description: Participate in virtual meetings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies